Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Pharmaceuticals has received final approval from the FDA on its abbreviated new drug application for bupropion hydrochloride extended-release tablets, 300mg.
Subscribe to our email newsletter
Bupropion hydrochloride extended-release is the generic equivalent to GlaxoSmithKline’s Wellbutrin XL tablets, which is indicated for the treatment of major depressive disorder. The company intends to launch the product immediately.